The Canadian ALS Neuroimaging Consortium (CALSNIC) - a multicentre platform for standardized imaging and clinical studies in ALS
Authors:
- Sanjay KalraSKSanjay Kalra
- Muhammad Umer KhanMKMuhammad Umer Khan
- Laura BarlowLBLaura Barlow
- Christian BeaulieuCBChristian Beaulieu
- Michael BenatarMBMichael Benatar
- Hannah BriembergHBHannah Briemberg
- Sneha ChenjiSCSneha Chenji
- Miriam Garrido CluaMCMiriam Garrido Clua
- Andre CormierACAndre Cormier
- Sumit DasSDSumit Das
- Annie DionneADAnnie Dionne
- Nicholas DupreNDNicholas Dupre
Preprint
Abstract
Background: Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. Increasing age is an important risk factor for developing ALS, thus the societal impact of this devastating disease will become more profound as the population ages. A significant hurdle to finding effective treatment has been an inability to accurately quantify cerebral degeneration associated with ALS in humans. Advanced magnetic resonance imaging (MRI) techniques hold promise in providing a set of biomarkers to assist in aiding diagnosis and in efficiently evaluating new drugs to treat ALS. Methods: The Canadian ALS Neuroimaging Consortium (CALSNIC) was founded to develop and evaluate advanced MRI-based biomarkers that delineate biological heterogeneity, track disease progression, and predict survival in a large and heterogeneous sample of ALS patients. Findings: CALSNIC has launched two studies to date (CALSINC-1, CALSNIC-2), acquiring multimodal neuroimaging, neurological, neuropsychological data, and neuropathological data from ALS patients and healthy controls in a prospective and longitudinal fashion from multiple centres in Canada and, more recently, the United States. Clinical and MRI protocols are harmonized across research centres and different MR vendors. Interpretation: CALSNIC provides a multicentre platform for studying ALS biology and developing MRI-based biomarkers. Funding: Canadian Institutes of Health Research, ALS Society of Canada, Brain Canada Foundation, Shelly Mrkonjic Research FundKeywords
This publication has 41 references indexed in Scilit:
- Fast progressive lower motor neuron disease is an ALS variant: A two-centre tract of interest-based MRI data analysisNeuroImage: Clinical, 2018
- Neuroimaging Endpoints in Amyotrophic Lateral SclerosisNeurotherapeutics, 2017
- Decoding ALS: from genes to mechanismNature, 2016
- A large-scale multicentre cerebral diffusion tensor imaging study in amyotrophic lateral sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2016
- Progress towards a neuroimaging biomarker for amyotrophic lateral sclerosisThe Lancet Neurology, 2015
- Towards a neuroimaging biomarker for amyotrophic lateral sclerosisThe Lancet Neurology, 2011
- EFNS guidelines on the use of neuroimaging in the management of motor neuron diseasesEuropean Journal of Neurology, 2010
- Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosisAmyotrophic Lateral Sclerosis, 2009
- Are amyotrophic lateral sclerosis patients cognitively normal?Neurology, 2003
- Prognosis in amyotrophic lateral sclerosisNeurology, 2003